Page 4 - Les meilleurs doctors traitant la maladie suivante : Cancer de l'intestin grêle - TOP -116 des médecins

Le Dr Muzaffer Al est spécialisé dans la chirurgie laparoscopique du cancer de l'intestin grêle, avec une formation avancée issue des meilleurs programmes médicaux de l'Université d'Istanbul.

• Chirurgien certifié avec plus de 20 ans d'expérience
• Expert en chirurgie laparoscopique antireflux et bariatrique
• Formé en chirurgie oncologique à la Faculté de médecine de Cerrahpaşa

Professeur en radio-oncologie avec plus de 20 ans de spécialisation dans le traitement du cancer – actuellement à l'Université Medipol d'Istanbul.

• Formation à l'Université d'Istanbul et à l'Université Kadir Has
• Maître de conférences puis Professeur titulaire à l'Université Demiroglu Bilim
• Travail dans les services de radio-oncologie des principaux hôpitaux d'Istanbul
• Prise en charge de cas complexes nécessitant une radiothérapie de précision

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

33 ans de spécialisation en oncologie et radiothérapie – Le Dr Auala Hubert dirige le centre des cancers gastro-intestinaux au Hadassah Medical Center.

• Certifié en oncologie et radiothérapie
• Diplômé de l'hôpital universitaire Hadassah
• Parle couramment l'anglais et l'hébreu
• Membre de plusieurs associations d'oncologie

Le professeur associé Nail Paksoy se spécialise dans les cancers gastro-intestinaux à l'hôpital Medipol Bahçelievler, avec un accent particulier sur le cancer de l'intestin grêle.

• Certifié par l'ESMO en oncologie médicale
• Sous-investigateur dans 8 essais cliniques internationaux pour les traitements du cancer
• Publication de nombreux articles de recherche sur les cancers gastro-intestinaux et rares
• Formation en fellowship à l'Institut d'oncologie de l'Université d'Istanbul

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Le Dr Alemdar est spécialisé dans le cancer de l'intestin grêle et possède une vaste formation en oncologie médicale à l'université Akdeniz.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience en médecine interne et en oncologie
• A travaillé à l'hôpital universitaire Akdeniz – un centre d’oncologie de premier plan
• Membre de l'Association turque d'oncologie médicale

Plus de 30 ans d'expérience en immunologie avec une spécialisation en virothérapie – Le Dr Jaunalksne dirige le centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins.

• Se spécialiser dans l'un des domaines les plus récents de l'immunologie
• Diplômée de l'Institut de médecine de Riga
• Effectuer un internat en médecine interne

Le Dr Ozden allie une formation académique à la prestigieuse faculté Cerrahpaşa de l'Université d'Istanbul à 6 ans de spécialisation en oncologie médicale.

• Certifié en médecine interne et en oncologie médicale
• Formé à l'Université de Kocaeli – reconnue pour ses soins oncologiques de pointe
• Plus de 15 ans de pratique clinique dans plusieurs centres hospitaliers

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Le Dr Kinas est spécialisé dans les cancers gastro-intestinaux complexes, y compris le cancer de l'intestin grêle, aux hôpitaux Büyük Anadolu.

• Expertise en chirurgie du pancréas et des voies biliaires
• Réaliser des chirurgies oncologiques pour divers cancers gastro-intestinaux
• Compétence en procédures bariatriques et métaboliques avancées

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Plus de 15 000 interventions chirurgicales effectuées, dont 1 000 techniques mini-invasives par an – le Dr de Lacy est un pionnier de la chirurgie gastro-intestinale à l'Hôpital Quirón Barcelone.

• Se spécialiser dans les traitements des cancers du rectum, du côlon et de l'œsophage
• Être le premier au monde à pratiquer l'ablation de la vésicule biliaire par la bouche
• Introduire la technique TaTME pour la chirurgie du cancer du rectum
• Être président de l'Association des chirurgiens-endoscopistes en Europe